| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
3,047 |
2,846 |
$307K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,595 |
2,427 |
$170K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
3,341 |
2,511 |
$109K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
601 |
559 |
$70K |
| G0378 |
Hospital observation service, per hour |
91 |
84 |
$55K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
7,257 |
6,479 |
$35K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
301 |
165 |
$18K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
281 |
272 |
$15K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
644 |
574 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
697 |
639 |
$1K |
| 70450 |
Computed tomography, head or brain; without contrast material |
803 |
772 |
$1K |
| 80053 |
Comprehensive metabolic panel |
6,242 |
4,961 |
$1K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
479 |
449 |
$856.26 |
| 84484 |
|
2,983 |
1,835 |
$792.33 |
| 71046 |
Radiologic examination, chest; 2 views |
460 |
446 |
$780.87 |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
26 |
26 |
$706.11 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,694 |
4,825 |
$598.64 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,961 |
2,545 |
$483.77 |
| 71045 |
Radiologic examination, chest; single view |
498 |
450 |
$195.01 |
| 82553 |
|
1,886 |
1,604 |
$192.91 |
| 84703 |
|
594 |
556 |
$188.46 |
| 81001 |
|
1,628 |
1,515 |
$143.88 |
| 83605 |
|
1,208 |
981 |
$140.54 |
| J2704 |
Injection, propofol, 10 mg |
3,456 |
1,738 |
$132.17 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
381 |
346 |
$128.81 |
| 82947 |
|
4,841 |
1,413 |
$102.88 |
| 82550 |
|
1,521 |
1,296 |
$63.92 |
| 83880 |
|
68 |
68 |
$63.65 |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
46 |
44 |
$53.70 |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
26 |
25 |
$52.70 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,308 |
1,111 |
$51.31 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
95 |
65 |
$46.68 |
| 87400 |
|
13 |
13 |
$41.27 |
| 85610 |
|
999 |
764 |
$36.13 |
| A9270 |
Non-covered item or service |
5,014 |
1,140 |
$33.45 |
| 83690 |
|
459 |
424 |
$28.52 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
39 |
27 |
$23.23 |
| 85730 |
|
118 |
110 |
$16.97 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
925 |
838 |
$15.35 |
| 83735 |
|
302 |
229 |
$14.38 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
381 |
241 |
$3.43 |
| 85027 |
|
347 |
264 |
$2.53 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
194 |
144 |
$0.23 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
1,229 |
943 |
$0.09 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
706 |
382 |
$0.00 |
| 87077 |
|
193 |
113 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
59 |
41 |
$0.00 |
| 87040 |
|
31 |
16 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
383 |
203 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
28 |
26 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
92 |
71 |
$0.00 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
45 |
38 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
41 |
36 |
$0.00 |
| 84100 |
|
86 |
67 |
$0.00 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
67 |
61 |
$0.00 |
| 81003 |
|
83 |
81 |
$0.00 |
| 87186 |
|
178 |
110 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
50 |
24 |
$0.00 |